On natural and artificial vaccinations

Annual Review of Immunology

Volumn 21, Issue , 2003, Pages 515-546

  Zinkernagel, Rolf M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Autoimmunity; Immunity; Immunological memory; Infections; Maternal antibodies; Tumors; Virus

Indexed keywords

BACTERIAL VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR; VACCINE; VIRUS VACCINE; CANCER VACCINE;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; BREAST MILK; CELL SYNCHRONIZATION; CELLULAR IMMUNITY; COLOSTRUM; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; DEGENERATIVE DISEASE; DENDRITIC CELL; EFFECTOR CELL; EVALUATION; HEART DILATATION; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE MEDIATED INJURY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; INFECTION RESISTANCE; INTESTINE EPITHELIUM; JUVENILE DIABETES MELLITUS; LETHALITY; MACROPHAGE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MATERNAL MORBIDITY; MEMORY CELL; MILK HYGIENE; MOLECULAR PHYLOGENY; PASSIVE IMMUNIZATION; PLASMA CELL; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; X CHROMOSOME; ANIMAL; B LYMPHOCYTE; FEMALE; IMMUNOLOGY; INFANT; INFECTION; PREGNANCY; PRESCHOOL CHILD; T LYMPHOCYTE; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CANCER VACCINES; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOLOGIC MEMORY; INFANT; INFECTION; PREGNANCY; T-LYMPHOCYTES; VACCINATION; VACCINES;

EID: 0041468871     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.21.120601.141045     Document Type: Review

References (133)

1. Hale JH. 1960. Duration of immunity in virus diseases. Adv. Immunol. 1:263-81
2. Beverley PC. 1990. Human T cell memory. Curr. Top. Microbiol. Immunol. 159:111-22
3. Gray D. 1993. Immunological memory. Annu. Rev. Immunol. 11:49-77
4. Mackay CR. 1993. Immunological memory. Adv. Immunol. 53:217-65
5. Zinkernagel RM, Bachmann MF, Kündig TM, Oehen S, Pircher HP, Hengartner H. 1996. On immunological memory. Annu. Rev. Immunol. 14:333-67
6. Ahmed R, Gray D. 1996. Immunological memory and protective immunity: understanding their relation. Science 272:54-60
7. Zinkernagel RM. 2000. On immunological memory. Philos. Trans. R. Soc. London Ser. B 355:369-71
8. Plotkin SA. 2001. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20:63-75
9. Nossal GJV. 1999. Vaccines. In Immunology, ed. WE Paul, pp. 1387-425. Philadelphia: Lippincott-Raven
10. Bloom B, Ahmed R. 1998. Immunity to infection. Curr. Opin. Immunol. 10:419-21
11. Mires CA. 1987. Pathogenesis of Infectious Disease. London: Academic
12. Ada G. 2000. HIV and pandemic influenza virus: two great infectious disease challenges. Virology 268:227-30
13. Kaufmann SHE. 1993. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11:129-63
14. Strohle A, Eggenberger K, Steiner CA, Matter L, Germann D. 1997. Mumps epidemic in vaccinated children in West Switzerland. Schweiz. Med. Wochenschr. 127:1124-33 (In German)
15. Wild TF. 1999. Measles vaccines, new developments and immunization strategies. Vaccine 17:1726-29
16. Janeway CA Jr. 2001. How the immune system works to protect the host from infection: a personal view. Proc. Natl. Acad. Sci. USA 98:7461-68
17. Fearon DT. 2000. Innate immunity-beginning to fulfill its promise? Nat. Immunol. 1:102-3
18. Fenner F, McAuslan B, Mims C, Sambrook J, White DO. 1974. The Biology of Animal Viruses, pp. 1-834. New York: Academic
19. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-21
20. Holmgren J, Brantzaeg P, Capron A, Francotte M, Kilian M, et al. 1996. European Commission COST/STD Initiative. Report of the expert panel VI. Concerted efforts in the field of mucosal immunology. Vaccine 14:644-64
21. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM. 2000. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288:2222-26
22. Zinkernagel RM. 1996. Immunology taught by viruses. Science 271:173-78
23. Kagi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. 1996. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 14:207-32
24. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29-60
25. Kappler JW, Roehm N, Marrack P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273-80
26. Kappler JW, Wade T, White J, Kushnir E, Blackman M, et al. 1987. A T cell receptor V beta segment that imparts reactivity to a class II major histocompatibility complex product. Cell 49:263-71
27. Kisielow P, Bluthmann H, Staerz UD, Steinmetz M, von Boehmer H. 1988. Tolerance in T-cell receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 333:742-46
28. Moskophidis D, Laine E, Zinkernagel RM. 1993. Peripheral clonal deletion of antiviral memory CD8+ T cells. Eur. J. Immunol. 23:3306-11
29. Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, et al. 1997. The role of antibody concentration and avidity in antiviral protection. Science 276:2024-27
30. Ochsenbein AF, Pinschewer DD, Odermatt B, Ciurea A, Hengartner H, Zinkernagel RM. 2000. Correlation of T cell independence of antibody responses with antigen dose reaching secondary lymphoid organs: implications for splenectomized patients and vaccine design. J. Immunol. 164:6296-302
31. Mitchison NA. 1971. The carrier effect in the secondary response to hapten-protein conjugates. V. Use of antilymphocyte serum to deplete animals of helper cells. Eur. J. Immunol. 1:68-75
32. Bachmann MF, Zinkernagel RM. 1997. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15:235-70
33. Möller G. 1975. One non-specific signal triggers b lymphocytes. Transplant. Rev. 23:126-37
34. Nathanson N. 1990. Epidemiology. See Ref. 132, pp. 267-91
35. Sabin AB. 1985. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151:420-36
36. Gupta SC, Hengartner H, Zinkernagel RM. 1986. Primary antibody responses to a well-defined and unique hapten are not enhanced by preimmunization with carrier: analysis in a viral model. Proc. Natl. Acad. Sci. USA 83:2604-8
37. Liang S, Mozdzanowska K, Palladino G, Gerhard W. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-61
38. Dimmock NJ. 1993. Neutralization of animal viruses. Curr. Top. Microbiol. Immunol 183:1-149
39. Roost H-P, Bachmann MF, Haag A, Kalinke U, Pliska V, et al. 1995. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc. Natl. Acad. Sci. USA 92:1257-61
40. Mackay IR. 1980. Immunology of chronic hepatitis. Ann. Acad. Med. Singapore 9:167-71
41. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, et al. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328(6128):345-48
42. Mackaness GB. 1964. The immunological basis of aquired cellular resistance. J. Exp. Med. 120:105-20
43. Blanden RV, Mackaness GB, Collins FM. 1966. Mechanisms of acquired resistance in mouse typhoid. J. Exp. Med. 124:585-600
44. Planz O, Ehl S, Furrer E, Horvath E, Brundler MA, et al. 1997. A critical role for neutralizing antibody-producing B cells, CD4+ T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA 94:6874-79
45. Ciurea A, Klenerman P, Hunziker L, Horvath E, Senn BM, et al. 2000. Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc. Natl. Acad. Sci. USA 97:2749-54
46. Bachmann MF, Kündig TM, Hengartner H, Zinkernagel RM. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"? Proc. Natl. Acad. Sci. USA 94:640-45
47. Kündig TM, Althage A, Hengartner H, Zinkernagel RM. 1992. Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. USA 89:7757-61
48. Rajewski K. 1989. Evolutionary and somatic immunological memory. In Progress in Immunology, Vol. VII, ed. F Melchers, ED Albert, H von Boehmer, MP Dierich, L Du Pasquier, et al, pp. 397-403. Berlin: Springer-Verlag
49. Bradley LM, Croft M, Swain SL. 1993. T cell memory: new perspectives. Immunol. Today 14:197-99
50. Fenner F. 1949. Mousepox (infectious ectromelia of mice): A review. J. Immunol. 63:341-73
51. Henderson DA. 1999. Lessons from the eradication campaigns. Vaccine 17(Suppl. 3):S53-55.
52. Zinkernagel RM. 2001. Maternal antibodies, childhood infections and autoimmune diseases. N. Engl. J. Med. 345:1331-35
53. Black FL, Hierholzer WJ, Pinheiro F, Evans AS, Woodall JP, et al. 1974. Evidence for persistence of infectious agents in isolated human populations. Am. J. Epidemiol. 100:230-50
54. Brambell RWR. 1970. The Transmission of Immunity from Mother to Young. Amsterdam: North Holland
55. Barker CF, Billingham RE. 1977. Immunologically privileged sites. Adv. Immunol. 25:1-54
56. Brent L. 1996. A History of Transplantation Immunology. New York: Academic
57. Good RA, Zak SJ. 1956. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18:109-49
58. Rawls WE. 1974. Viral persistence in congenital rubella. Prog. Med. Virol. 18:273-88
59. TORCH syndrome and TORCH screening. 1990. Lancet 335:1559-61
60. Mackaness GB. 1969. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J. Exp. Med. 129:973-92
61. Collins FM, Mackaness GB, Blanden RV. 1966. Infection-immunity in experimental salmonellosis. J. Exp. Med. 124:601-19
62. Zinkernagel RM. 2000. Localization dose and time of antigens determine immune reactivity. Semin. Immunol. 12:163-71
63. Gray D, Skarvall H. 1988. B cell memory is short-lived in the absence of antigen. Nature 336:70-73
64. Ochsenbein AF, Pinschewer DD, Sierro S, Horvath E, Hengartner H, Zinkernagel RM. 2000. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc. Natl. Acad. Sci USA 97:13263-68
65. Zinkernagel RM. 2002. On differences between immunity and immunological memory. Curr. Opin. Immunol. 14:523-36
66. Slifka MK, Ahmed R. 1998. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10:252-58
67. Steinhoff U, Müller U, Schertler A, Hengartner H, Aguet M, Zinkernagel RM. 1995. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor deficient mice. J. Virol. 69:2153-58
68. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A. 1998. Survival of long-lived plasma cells is independent of antigen. Int. Immunol. 10:1703-11
69. Guris D, McCready J, Watson JC, Atkinson WL, Heath IL, et al. 1996. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr. Infect. Dis. J. 15:1082-86
70. Ochsenbein AF, Karrer U, Klenerman P, Althage A, Ciurea A, et al. 1999. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc. Natl. Acad. Sci. USA 96:9293-98
71. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Stevenson PG. 1997. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol. Rev. 159:105-17
72. von Pirquet C. 1907. On clinical studies about vaccination and vaccinal allergies. Leipzig: Denticke (In German)
73. Albert MR, Ostheimer KG, Breman JG. 2001. The last smallpox epidemic in Boston and the vaccination controversy, 1901-1903. N. Engl. J. Med. 344:375-79
74. Roost H-P, Charan S, Zinkernagel RM. 1990. Analysis of the kinetics of antiviral memory T help in vivo: characterization of short-lived cross-reactive T help. Eur. J. Immunol. 20:2547-54
75. Kapoor AK, Nash AA, Wildy P. 1982. Pathogenesis of herpes simplex virus in B cell-suppressed mice: the relative roles of cell-mediated and humoral immunity. J. Gen. Virol. 61(Pt. 1):127-31
76. Zinkernagel RM. 2000. What is missing in immunology to understand immunity? Nat. Immunol. 1(3):181-85
77. Melnick JL. 1990. Enteroviruses. See Ref. 132, pp. 549-605
78. Kaplan MH, Klein SW, McPhee J, Harper RG. 1983. Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev. Infect. Dis. 5:1019-32
79. Narayan KM, Moffat MA. 1992. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland. Health Bull. 50:47-53
80. Sarvas H, Kurikka S, Seppala IJ, Makela PH, Makela O. 1992. Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants. J. Infect. Dis. 165:977-79
81. Watanabe M. 2001. Polio outbreak threatens eradication program. Nat. Med. 7:135
82. Billeter MA, Cattaneo R, Spielhofer P, Kaelin K, Huber M, et al. 1994. Generation and properties of measles virus mutations typically associated with subacute sclerosing panencephalitis. Ann. NY Acad. Sci. 724:367-77
83. Katayama Y, Hotta H, Nishimura A, Tatsuno Y, Homma M. 1995. Detection of measles virus nucleoprotein mRNA in autopsied brain tissues. J. Gen. Virol. 76:3201-4
84. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. 1996. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2:1-6
85. Ciurea A, Klenerman P, Hunziker L, Horvath E, Odermatt B, et al. 1999. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc. Natl. Acad. Sci. USA 96:11964-69
86. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, et al. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-29
87. Nossal GJV, Austin CM, Ada GL. 1965. Antigens in immunity: VII. Analysis of immunological memory. Immunology 9:333
88. Tew JG, Kosco MH, Burton GF, Szakal AK. 1990. Follicular dendritic cells as accessory cells. Immunol. Rev. 117:185-211
89. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. 1998. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today 19:368-73
90. + T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1-77
91. Zinkernagel RM. 2002. On cross-priming of MHC class I-specifc CTL: rule or exception? Eur. J. Immunol. 32:2385-92
92. Albert ML, Sauter B, Bhardwaj N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89
93. Sigal LJ, Crotty S, Andino R, Rock KL. 1999. Cytotoxic T-cell immunity to virus-infected nonhaematopoietic cells requires presentation of exogenous antigen. Nature 398:77-80
94. Bloom BR, Murray CJ. 1992. Tuberculosis: commentary on a re-emergent killer. Science 257:1055-1064.
95. Le Page C, Genin P, Baines MG, Hiscott J. 2000. Interferon activation and innate immunity. Rev. Immunogenet. 2:374-86
96. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702
97. Manabe YC, Bishai WR. 2000. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat. Med. 6:1327-29
98. McKinney JD, zu Bentrup BK, Munoz-Elias EJ, Miczak A, Chen B, et al. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406:735-38
99. Fauci AS, Pantaleo G, Stanley S, Weissman D. 1996. Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 124:654-63
100. Ruprecht RM. 1999. Live attenuated AIDS viruses as vaccines: promise or peril? Immunol. Rev. 170:135-49.
101. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-18
102. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, et al. 1999. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:6721-28
103. Chun TW, Justement JS, Moir S, Hallahan CW, Ehler LA, et al. 2001. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: Implications for the development of therapeutic strategies. Proc. Natl. Acad. Sci. USA 98:253-58
104. Tremblay M, Wainberg MA. 1990. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis. 162:735-37
105. Trkola A, Ketas T, Kewalramani VN, Endorf F, Binley JM, et al. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-85
106. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-50
107. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, et al. 1990. Direct gene transfer into mouse muscle in vivo. Science 247:1465-68
108. Robinson HL, Pertmer TM. 2000. DNA vaccines for viral infections: basic studies and applications. Adv. Virus Res. 55:1-74
109. Frazer IH. 1996. Immunology of papillomavirus infection. Curr. Opin. Immunol. 8:484-91
110. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, et al. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T cell induction. Nature 411:1058-64
111. Albert ML, Pearce SFA, Francisco LM, Sauter B, Roy P, et al. 1998. Immature dendritic cells phagocytose apoptotic cells via alpha/beta 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359-68
112. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, et al. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96:2233-38
113. Garenne M, Leroy O, Beau JP. 1991. Child mortality after high titer measles; prospective study in Senegal. Lancet 388:903-7
114. Nader PR, Horwitz MS, Rousseau J. 1968. Atypical exanthem following exposure to natural measles: Eleven cases in children previously inoculated with killed vaccine. J. Pediatr. 72:22-28
115. Osborn JJ, Dancis J, Julia JF. 1952. Studies of the immunology of the newborn infant. Pediatrics 10:328-34
116. Burnet FM, Fenner FJ. 1949. The Production of Antibodies (Monogr.) Melbourne: Macmillan Walter and Eliza Hall Instiute
117. Siegrist CA, Barrios C, Martinez X, Brandt C, Berney M, et al. 1998. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur. J. Immunol. 28:4138-48
118. Sabin AB, Arechiga AF, DeCastro JF, Sever JL, Madden DL, et al. 1983. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 249:2651-62
119. Englund J, Glezen WP, Piedra PA. 1998. Maternal immunization against viral disease. Vaccine 16:1456-63
120. Graham DG, Gordon A, Ashworth B, Yap PL. 1983. Immunodeficiency measles encephalitis. J. Clin. Lab. Immunol. 10:117-20
121. Malfait P, Jataou IM, Jollet MC, Margot A, De Benoist AC, Moren A. 1994. Measles epidemic in the urban community of Niamey: transmission patterns, vaccine efficacy and immunization strategies, Niger, 1990 to 1991. Pediatr. Infect. Dis. J. 13:38-45
122. WHO Study Group on Oral Polio Vaccine. 1995. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J. Infect. Dis. 171:1097-106
123. Booy R, Aitken SJ, Taylor S, Tudor-Williams G, Macfarlane JA, et al. 1992. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 339:507-10
124. Norrby E. 1978. Viral antibodies in multiple sclerosis. Prog. Med. Virol. 24:1-39
125. Stephenson JR, ter Meulen V, Kiessling W. 1980. Search for canine-distemper-virus antibodies in multiple sclerosis. A detailed virological evaluation. Lancet 2:772-75
126. Dahlquist G, Frisk G, Ivarsson SA. 1995. Indications that maternal coxsackie B virus infection during pregnancy is a risk factor for childhood-onset IDDM. Diabetologia 38:1371-73
127. Goren A, Kaplan M, Glaser J, Isacsohn M. 1989. Chronic neonatal coxsackie myocarditis. Arch. Dis. Child 64:404-6
128. Woodruff JF, Woodruff JJ. 1974. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J. Immunol. 113:1726-34
129. Herzum M, Huber SA, Weller R, Grebe R, Maisch B. 1991. Treatment of experimental murine Coxsackie B3 myocarditis. Eur. Heart J. 12(Suppl. D):200-2
130. Kandolf R. 1996. Myocarditis and cardiomyopathy. Verh. Dtsch. Ges. Pathol. 80:127-38 (In German)
131. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191:795-804
132. Nathanson N, Martin JR. 1979. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am. J. Epidemiol. 110:672-92
133. Fields, BN, Knipe DM, eds. 1990. Virology. New York: Raven